Debt-to-EBITDA measures a company's ability to pay off its debt.
Walgreens Boots Alliance's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2022 was $5,056 Mil. Walgreens Boots Alliance's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2022 was $32,220 Mil. Walgreens Boots Alliance's annualized EBITDA for the quarter that ended in May. 2022 was $2,272 Mil.
Walgreens Boots Alliance's annualized Debt-to-EBITDA for the quarter that ended in May. 2022 was 16.41.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Walgreens Boots Alliance's Debt-to-EBITDA or its related term are showing as below:
WBA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.89 Med: 1.84 Max: 13.26
Current: 4.63
During the past 13 years, the highest Debt-to-EBITDA Ratio of Walgreens Boots Alliance was 13.26. The lowest was 0.89. And the median was 1.84.
WBA's Debt-to-EBITDA is ranked worse than 71.43% of 420
companies
in the Healthcare Providers & Services industry
Industry Median: 2.58
vs WBA: 4.63
Walgreens Boots Alliance Debt-to-EBITDA Historical Data
The historical data trend for Walgreens Boots Alliance's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Walgreens Boots Alliance Annual Data
Trend
Aug12
Aug13
Aug14
Aug15
Aug16
Aug17
Aug18
Aug19
Aug20
Aug21
Debt-to-EBITDA
1.80
1.72
2.39
13.26
6.85
Walgreens Boots Alliance Quarterly Data
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Feb19
May19
Aug19
Nov19
Feb20
May20
Aug20
Nov20
Feb21
May21
Aug21
Nov21
Feb22
May22
Debt-to-EBITDA
5.57
5.52
2.17
5.97
16.41
Competitive Comparison
For the Pharmaceutical Retailers subindustry, Walgreens Boots Alliance's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Walgreens Boots Alliance Debt-to-EBITDA Distribution
For the Healthcare Providers & Services industry and Healthcare sector, Walgreens Boots Alliance's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Walgreens Boots Alliance's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (May. 2022) EBITDA data.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Walgreens Boots Alliance Debt-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Walgreens Boots Alliance's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Walgreens Boots Alliance is a leading retail pharmacy chain, with over 13,000 stores in 50 states and 9 countries. Walgreens' core strategy involves brick-and-mortar retail pharmacy locations in high-traffic areas, with nearly 80% of the U.S. population living within 5 miles of a store. Currently, the company has a leading market share of the domestic prescription drug market at about 20%. In 2021, the company sold off a majority of its Alliance Healthcare wholesale business to AmerisourceBergen for $6.5 billion, doubling down on its core pharmacy efforts and ventures in strategic growth areas in primary care (VillageMD) and digital offerings. The company also has equity stakes in AmerisourceBergen (29%) and Sinopharm Holding Guoda Drugstores (40%).
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.52(1.3%) Volume: 4,413,264 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:WBA has been successfully added to your 
